Concurrent Small-Cell Transformation and Emergence of Trans-C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma

Elio G. Pizzutilo, MD1,2; Calogero Lauricella, PhD1; Giulio Cerea, MD1; Laura G. Giannetta, MD1; Gianluca Tomasello, MD1; Stefano Stabile, PhD1; Valentina Motta, PhD1; Spyridon Alexiadis, MD1; Francesco Scaglione, MD, PhD1,2; Angelo Vanzulli, MD1,2; Massimo Torre, MD1; Emanuela Bonoldi, MD1; Silvio M. Veronese, PhD1; Salvatore Siena, MD1,2; and Andrea Sartore-Bianchi, MD1,2 Show…

Read the full article here

Source: JCO Precision Oncology

Categories: Hem/Onc News and Journals

Tags: lcsm

Tweets with this article

ASCO Publications

Concurrent Small-Cell Transformation and Emergence of C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma https://t.co/Eh1WHfjEpB #lcsm #JCOPO https://t.co/AsonDJh321

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer | Journal of Clinical Oncology

PURPOSE To evaluate the activity and safety of nivolumab with nab-paclitaxel as neoadjuvant therapy, followed by radical cystectomy (RC) and postsurgical adjuvant nivolumab in patients…

ASCO Publications September 12, 2024

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study | Journal of Clinical Oncology

PURPOSE Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in ESR1-mutant breast cancer. This phase…

ASCO Publications September 12, 2024

Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial | Journal of Clinical Oncology

PURPOSE We aim to determine the effectiveness of adding electroacupuncture to standard triple antiemetic therapy for treating chemotherapy-induced nausea and vomiting (CINV). METHODS From March…

ASCO Publications September 12, 2024

Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis | Journal of Clinical Oncology

PURPOSE Chronic lymphocytic leukemia (CLL)-phenotype monoclonal B-cell lymphocytosis (MBL) is a premalignant condition that is roughly 500-fold more common than CLL. It is unknown whether…

ASCO Publications September 12, 2024

Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors | Journal of Clinical Oncology

PURPOSE BT5528 is a Bicycle Toxin Conjugate, a novel class of chemically synthesized molecules, comprising a bicyclic peptide targeting EphA2 tumor antigen, linked to a…

ASCO Publications September 11, 2024

Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis | Journal of Clinical Oncology

PURPOSE The adjuvant treatment for stage III colon cancer (CC) is chemotherapy combining fluoropyrimidine (FP) and oxaliplatin (OX). FP regimen plus OX (FPOX) may benefit…

ASCO Publications September 11, 2024

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy | Journal of Clinical Oncology

PURPOSE Sacituzumab govitecan (SG) is a Trop-2–directed antibody-drug conjugate with an SN-38 payload, approved for patients with locally advanced (LA) or metastatic urothelial cancer (mUC)…

ASCO Publications September 11, 2024

Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926 | Journal of Clinical Oncology

PURPOSE To investigate the use of radiation with radiosensitizing chemotherapy following repeated transurethral resection (trimodality therapy) as an alternative to radical cystectomy in T1 bladder…

ASCO Publications September 10, 2024

Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs | Journal of Clinical Oncology

PURPOSE The advent of new therapeutic modalities highlighted deficiencies in the traditional maximum tolerated dose approach for oncology drug dose selection and prompted the Food…

ASCO Publications September 10, 2024

Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records | Journal of Clinical Oncology

PURPOSE Current approaches to accurately identify immune-related adverse events (irAEs) in large retrospective studies are limited. Large language models (LLMs) offer a potential solution to…

ASCO Publications September 10, 2024

Related Articles